Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Biological therapies should be considered in patients with high disease activity despite nonsteroid antiinflammatory drug treatment. The first option among biological therapies is anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown that clinical and ultrasonographic enthesitis may improve as well as disease activity, quality of life and acute phase reactants. In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis

NCT01298531

Axial Spondyloarthritis

COMPLETED PHASE4

Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"

NCT02878161

Rheumatoid Arthritis

UNKNOWN PHASE4

Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes

NCT01258738

Spondylitis, Ankylosing

COMPLETED PHASE3

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

NCT06601595

Inflammatory Bowel Disease (IBD) Spondylarthropathies TNF-alpha Inhibitors

NOT_YET_RECRUITING

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

NCT00000433

Spondylitis, Ankylosing

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondyloarthritis Enthesitis Anti-Tumor Necrosis Factor Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

All patients were evaluated by the researcher who had a 10-year experience of musculoskeletal ultrasonography and is blind to clinical evaluation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spondyloarthritis

Spondyloarthritis patients who was initiated TNF alfa blocker

Group Type EXPERIMENTAL

TNF Inhibitor

Intervention Type DRUG

TNF inhibitors are widely used in patients with spondyloarthritis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TNF Inhibitor

TNF inhibitors are widely used in patients with spondyloarthritis

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spondyloarthritis patients were diagnosed according to 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria

Exclusion Criteria

* Severe cardiovascular and respiratory diseases,
* Severe liver and kidney failure,
* Pregnancy and lactation,
* Active infection,
* Malignancy,
* Demyelinating diseases,
* Systemic lupus erythematosus,
* History of knee, elbow, foot and ankle surgery,
* Fluoroquinolone, retinoid and fluoride use,
* Local corticosteroid injection at the examination sites within the six weeks before evaluation
* Peripheral neuropathy

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No